MedAssets Inc. Reaches New 12-Month High at $25.85 (MDAS)
MedAssets (NASDAQ:MDAS) set a new 52-week high on Thursday, Stock Ratings News reports. The company traded as high as $25.85 and last traded at $25.72, with a volume of 201,398 shares. The stock had previously closed at $25.38.
A number of research firms have recently commented on MDAS. Analysts at Robert W. Baird raised their price target on shares of MedAssets from $27.00 to $28.00 in a research note to investors on Thursday. They now have an “outperform” rating on the stock. Separately, analysts at ISI Group raised their price target on shares of MedAssets from $23.50 to $28.00 in a research note to investors on Monday. They now have a “neutral” rating on the stock. Finally, analysts at Raymond James downgraded shares of MedAssets from a “strong-buy” rating to a “market perform” rating in a research note to investors on Tuesday, October 1st. Six investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $26.83.
MedAssets has a 52 week low of $15.40 and a 52 week high of $25.72. The stock has a 50-day moving average of $24.35 and a 200-day moving average of $20.56. The company has a market cap of $1.586 billion and a P/E ratio of 378.81.
MedAssets (NASDAQ:MDAS) last released its earnings data on Wednesday, July 31st. The company reported $0.30 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.26 by $0.04. The company had revenue of $170.70 million for the quarter, compared to the consensus estimate of $167.64 million. During the same quarter in the prior year, the company posted $0.28 earnings per share. The company’s quarterly revenue was up 4.7% on a year-over-year basis. Analysts expect that MedAssets will post $1.31 EPS for the current fiscal year.
MedAssets, Inc (NASDAQ:MDAS) provides technology-enabled products and services.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.